In summary, our data presented herein suggest that Syk (L) isoform may be a target for the treatment of the majority of colorectal cancers, except a small group of tumors that express high levels of Syk (S) isoform and a strong decrease of Syk (L) isoform expression. The gene discussed is SYK; the disease is colorectal cancer.